Business
Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update
– Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue – – Strong Capital Position with over $300 Million
About this update from Esperion Therapeutics, Inc.
[{"type":"text","content":"– Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue –\n – Strong Capital Position with over $300 Million in Cash – – Extraordinary High-Quality Managed Care Coverage with Over 80% Commercial and Over 50% Medicare Part D Formulary Coverage – – Consistently High Month-Over-Month Growth for New Medicines With Acceleration in Second Half – – Conference Call and Webcast on August 10 at 4:30 P.M. Eastern Time – ANN ARBOR, Mich., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the second quarter ended June 30, 2020, which included the highest quarterly and first half revenue in Company history and other updates, including the establishment of a strong commercial foundation to further accelerate the launch of NEXLETOL® (bempedoic acid) tablets and NEXLIZET™ (bempedoic acid and ezetimibe) tablets in the second half of 2020. “Esperion is in a stronger position today than ever before, fortified by the significant business achievements of our Lipid Management Team. We successfully navigated through the unprecedented environment created by the COVID-19 pandemic to launch our first two medicines, deliver on our partnerships in Japan and Europe, and strengthen our balance sheet,” said Tim M. Mayleben, president and chief executive officer of Esperion. “The early feedback from U.S. healthcare providers and payers on NEXLETOL® and NEXLIZET™ has been extraordinary, reflecting strong positioning as affordable, complementary, convenient, oral, once-daily LDL-C lowering medicines and further confirmed by the broad, high-quality managed care coverage we’ve already secured so early in our commercial launch. While stay at home orders that were in effect across the U.S. for most of the quarter shifted the deployment of our field sales team, July prescription volumes demonstrate that all the pieces are now in place for healthcare providers and patients to access our medicines in volume.” Recent Highlights Clinical and Regulatory: April 2020: European Commission Marketing Approvals of NILEMDO™ (bempedoic acid) and NUSTENDI™ (bempedoic acid and ezetimibe) tablets for the treatment of hypercholesterolemia and mixed dyslipidemia.July 2020: Pooled LDL-C lowering efficacy analysis from the four Phase 3 clinical studies of NEXLETOL was published in the Journal o...